Diverse Biotech Secures Patents for Novel Antibody-Cannabinoid and Antibiotic-Cannabinoid Conjugates
Key Insights
Diverse Biotech Inc. (search) has received USPTO (search) patent protection for two groundbreaking drug conjugate technologies that combine antibodies or antibiotics with cannabinoids through specialized linkers.
The patented conjugates utilize a dual-mechanism approach where the primary component delivers targeted therapy while triggering localized cannabinoid release for synergistic therapeutic effects.
These innovations target the multi-billion dollar antibody market valued at $245-267 billion in 2024 and projected to reach $412-970 billion by 2030-2034.
Diverse Biotech Inc. (search) has achieved significant intellectual property milestones with the granting of U.S. Patent No. 11,877,988 B2 for antibody-cannabinoid conjugates and receipt of a Notice of Allowance for antibiotic-cannabinoid conjugates, positioning the company to disrupt established pharmaceutical markets with novel dual-action therapeutics.
Revolutionary Dual-Mechanism Technology
The patented technologies describe multifunctional conjugate molecules that covalently attach therapeutic antibody or β-lactam antibiotic components to cannabinoid components via specialized linkers. This sophisticated design enables dual therapeutic benefits through distinct mechanisms of action, representing a significant advancement over traditional single-target therapies.
The antibody-cannabinoid conjugates leverage the antibody component for precise delivery to specific disease sites or cells, such as cancer cells or inflammatory sites. Upon the antibody's binding to its target, the specialized linker enables controlled and localized release of cannabinoids like Cannabidiol (CBD) or Cannabigerol (CBG (search)) directly at the site of action, allowing the cannabinoid to exert a second therapeutic benefit.
Similarly, the antibiotic-cannabinoid conjugates combine β-lactam antibiotics with cannabinoids, where the covalent binding of the antibiotic component to its specific biological target triggers the controlled, localized release of the cannabinoid for complementary therapeutic effects.
Scientific Foundation and Mechanism
The technology's scientific basis centers on the generation and impact of Reactive Oxygen Species (ROS) in cellular health and disease. Research indicates that cannabinoids like CBD and CBG (search) can promote ROS generation within cells, including superoxide, hydrogen peroxide, and hydroxyl radicals. This controlled increase in ROS at disease sites can trigger apoptosis in undesirable cells, such as cancer cells, providing a potent, targeted cytotoxic effect that complements the primary action of the antibody or antibiotic.
Compelling research has demonstrated that all classes of bactericidal antibiotics promote the generation of lethal hydroxyl radicals in both Gram-negative and Gram-positive bacteria, contributing significantly to their antimicrobial action. CBD has shown promising anti-tumor activity in multiple cancer types through ROS induction, reducing glutathione and activating caspases involved in apoptotic pathways. CBG (search) exhibits potent anti-tumor activity by selectively increasing ROS production and influencing the inflammatory microenvironment.
Market Impact and Commercial Potential
The global antibody market represents a cornerstone of modern medicine, particularly in oncology and autoimmune diseases. Valued at approximately $245 billion to $267 billion USD in 2024, this market is projected to grow substantially, reaching an estimated $412 billion to over $970 billion USD by 2030-2034.
Diverse Biotech's technology addresses several market opportunities through enhanced efficacy by combining precise targeting with localized therapeutic effects, novel therapeutic avenues for next-generation antibody-drug conjugates using cannabinoids as payloads, and extended drug lifespan for antibodies nearing patent expiration through conjugation with cannabinoids via the patented technology.
"Diverse Biotech Inc. (search) is not just participating in the antibody market; we are redefining it," stated William Fisher, Director and Board Chairman of Diverse Biotech Inc. "Our fully granted patent US 11,877,988 B2, building upon our initial foundational patent US 20230173079 A1, is a testament to our position as world leaders in cannabinoid drug technology."
Development Strategy
The company has developed all groundbreaking technology in-house, from conception to patent approval, ensuring proprietary control and maximizing value capture. Diverse Biotech is actively pursuing partnerships and further development of these conjugates, aiming to bring these transformative therapies to patients worldwide.
Fisher emphasized the transformative potential: "This patent does not just represent a new molecule; it establishes an entirely new class of drugs with unprecedented therapeutic potential. By synergistically combining the proven power of β-lactam antibiotics with the emerging, complementary benefits of cannabinoids through a targeted delivery system, we are creating a unique competitive advantage."
The company is strategically positioned to capitalize on this intellectual property, with plans to accelerate preclinical and clinical development of these novel therapeutics targeting intractable infections, various forms of cancer, and potentially other diseases where conventional approaches fall short.